Hematologic Diseases: From Cellular and Molecular Mechanisms to Therapies

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: 30 April 2026 | Viewed by 116

Special Issue Editors

Division of Hematology and Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
Interests: normal and abnormal hematopoiesis; DNA damage repair; aging; hematopoietic stem cell-bone marrow niche interaction
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Biobank of Research, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Medical and Surgical Sciences (DIMEC), Bologna University, Bologna, Italy
Interests: leukemia; lymphoma; targeted therapy; molecular diagnostics; high throughput genomics; transcriptomics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Background and Significance
Hematologic disorders, encompassing malignant (e.g., leukemias, lymphomas, plasma cell neoplasms) and non-malignant entities (e.g., hemoglobinopathies, marrow failure syndromes, coagulopathies), contribute substantially to global morbidity and mortality. Advances in genomics, single-cell technologies, proteomics, and systems biology have elucidated critical mechanisms, including somatic mutations, epigenetic alterations, transcriptional dysregulation, and niche-mediated signaling. These insights have refined our understanding of disease ontogeny and progression.

Nevertheless, clinical translation remains a major challenge. Malignant hematologic diseases often exhibit clonal heterogeneity, dynamic evolution, and therapeutic resistance. Non-malignant conditions frequently lack mechanistic clarity and effective treatment paradigms. The advent of targeted agents, immunotherapies, and gene- and cell-based strategies underscores the need for integrative, mechanistically driven research across the translational spectrum.

Scope and Objectives
This Special Issue aims to showcase advances in the molecular and cellular pathogenesis of hematologic diseases and their implications for diagnosis, prognosis, and therapy. We invite original research, reviews, and communications addressing the following:

  • Clonal evolution and molecular pathogenesis;
  • Epigenetic and transcriptional regulation;
  • Drug resistance mechanisms;
  • Targeted and immune-based therapies;
  • Biomarker discovery;
  • Gene editing, stem cell biology, and cell-based interventions.

Our goal is to promote mechanistic insights that inform therapeutic innovation and improve clinical outcomes.

Dr. Wei Du
Dr. Pier Paolo Piccaluga
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hematologic diseases
  • mechanisms
  • therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 1274 KB  
Review
The Non-Coding RNome Landscape in Erythropoiesis: Pathophysiological Implications
by Emma Brisot, Laurent Metzinger and Valérie Metzinger-Le Meuth
Cells 2025, 14(24), 1971; https://doi.org/10.3390/cells14241971 - 11 Dec 2025
Abstract
Erythropoiesis is a multistage process critical for red blood cell production and systemic oxygen transport. It is tightly regulated, and recent advances have highlighted the pivotal regulatory roles of non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), in governing both [...] Read more.
Erythropoiesis is a multistage process critical for red blood cell production and systemic oxygen transport. It is tightly regulated, and recent advances have highlighted the pivotal regulatory roles of non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), in governing both physiological and pathological erythropoiesis. These ncRNAs have roles in the fine-tuning of the classical transcriptional and post-transcriptional control. This review explores the complex landscape of the non-coding RNome in erythroid differentiation, maturation, and function. We summarize how specific miRNAs influence erythroid lineage commitment, hemoglobin switching, iron metabolism, and cellular morphology, as well as their modulation by environmental and pathological cues. We also discuss emerging evidence on lncRNAs regulating chromatin remodeling, alternative splicing, apoptosis, enucleation, and erythroid-specific gene expression. These insights suggest that ncRNAs are instrumental orchestrators of erythropoiesis and accordingly, potential biomarkers and therapeutic targets in anemia and related hematologic disorders. Full article
Show Figures

Figure 1

Back to TopTop